Despite the popularity of semaglutide drugs like Ozempic and Wegovy for weight loss, surveys suggest that most people still ...

As of late 2024, only 14 state Medicaid programs cover GLP-1 drugs like Wegovy, Saxenda, or Zepbound for the treatment of obesity. These states are: California, Connecticut, Indiana, Maryland, ...

After adjusting for the weight loss benefits of surgery, GLP-1 drugs were linked to a 41% lower risk of obesity-related ...

Xavier said that patients are often reluctant to quit smoking because they are fearful that they will gain weight. By adding ...

Columnist Jen Cueva talks with her friend Lynda Pinto, who has PH, about Lynda's experience with GLP-1 agonist medications.

New review confirms psychiatric safety of commonly used glucagon-like peptide 1 receptor agonists among patients without ...

GLP-1 RAs are associated with a significant decrease in apnea-hypopnea index among patients with moderate to severe OSA and without diabetes.

GLP-1 receptor agonists are associated with improvements in restrained eating, emotional eating behavior, QOL.

The popularity of cottage cheese recipes, protein powders, and even Khloé Kardashian's popcorn launch prove a shift toward a ...

Treating nicotine addiction with glucagon-like peptide 1 receptor agonists is associated with less weight gain compared with ...

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...

The recent decision by some US states to cover glucagon-like peptide-1 (GLP-1) agonists for obesity treatment marks a shift ...